Farther Finance Advisors’s Rapport Therapeutics RAPP Stock Holding History

Farther Finance Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$34	Buy	+1	New	+$43	﹤0.01%	6045
2026 Q1	–	Sell	-1	Closed	-$30	–	5921
2025 Q4	$30	Buy	+1	New	+$28	﹤0.01%	5377

Other funds holding RAPP

CPW

Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors's RAPP Position: Q3 2026 in Review

Farther Finance Advisors opened a new position in Rapport Therapeutics (RAPP) in Q3 2026: 1 share worth $34. The stake represents ﹤0.01% of the portfolio and ranks #6045 among its holdings. This is a return to the name: Farther Finance Advisors previously reported a position in RAPP as recently as Q4 2025.

Farther Finance Advisors first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Farther Finance Advisors held 1 share of Rapport Therapeutics worth $34 as of Q3 2026.
Rapport Therapeutics was a new Farther Finance Advisors position in Q3 2026.
Rapport Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #6045 holding.
Farther Finance Advisors first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
8 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.